Navigation Links
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Date:5/28/2009

atic colorectal cancer," said Robert De Jager, M.D., chief medical officer of Poniard. "We are continuing to observe the study participants to obtain overall survival data, and expect those data later this year. The new PFS, tumor response and neurotoxicity data provide the rationale to consider additional trials to develop picoplatin as a preferred platinum for the treatment of metastatic colorectal cancer."

Analyst and Investor Briefing

Poniard will host an investor event in Orlando on Sunday, May 31, 2009. Presentations will begin promptly at 6:00 p.m. Eastern Time. The event will feature presentations and discussion with expert oncologists, including Richard Goldberg, M.D., of the University of North Carolina's Lineberger Comprehensive Cancer Center, William Oh, M.D., of Harvard Medical School, and David S. Ettinger, M.D., of the Kimmel Comprehensive Cancer Center at Johns Hopkins, in addition to members of Poniard's senior management team. The analyst meeting will also be simultaneously Webcast from Poniard's Web site at www.poniard.com and will remain available for 30 days following the live event.

About Colorectal Cancer

CRC is the third most common cancer in both American men and women, and the third leading cause of cancer death in the U.S. In 2008, an estimated 148,810 new cases of colon and rectal cancer were expected to be diagnosed in the U.S., with an estimated 49,960 deaths.(1) A FOLFOX-containing regimen is the current standard of care but is associated with a high incidence of neuropathy. Discontinuation of oxaliplatin from FOLFOX is recommended by the National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology (v.2.2009) after three months of therapy or sooner if significant neurotoxicity (> Grade 3) occurs, with other drugs maintained until the time of tumor progression.

About Picoplatin

Picoplatin
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
2. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
3. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
4. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
5. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
6. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
7. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
8. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
9. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
10. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013  Milliman, Inc., a ... results of its 2013 Milliman Medical Index (MMI), which ... of four receiving healthcare benefits through an employer-sponsored preferred ... this typical family in 2013 is $22,030. ... the prior year on a percentage basis was the ...
(Date:5/22/2013)... 2013  Modern Medical announced today the nationwide ... November 2012 in a test phase, ODM is ... the rising opioid abuse in the workers, compensation ... to protect employees, physicians and employers by reducing ... to provide pain relief for the injured worker.  ...
(Date:5/22/2013)... -- Pomerantz Grossman Hufford Dahlstrom ... investors of Intuitive Surgical, Inc. ("Intuitive Surgical" or the ... purchased Intuitive Surgical common stock between October 19, 2011 ... are advised to contact Robert S. Willoughby ... 237. The investigation concerns whether Intuitive Surgical ...
Breaking Medicine Technology:Annual Healthcare Cost for a Typical American Family is $22,030 According to 2013 Milliman Medical Index 2Modern Medical Introduces Opioid Abuse Solution to the Workers' Compensation Industry 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG 2
... N.J., Sept. 23 NeoStem, Inc. (NYSE Amex: ... in the U.S. and China and Progenitor Cell Therapy, ... the cell therapy industry from licensed, state-of-the art cell ... jointly announced the signing of a  definitive merger agreement ...
... which represents the interests of the worldwide mobile communications ... Awards programme. New categories have been added to recognise ... evolving mobile ecosystem. Specifically, the GSMA will shine a ... – space for the first time. "Health ...
Cached Medicine Technology:NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement 2NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement 3NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement 4GSMA's Global Mobile Awards To Recognise Mobile Innovation in the mHealth Sector 2
(Date:5/22/2013)... Los Angeles, CA (PRWEB) May 22, 2013 ... therapy4parents.com , hosted by Patricia O’Laughlin Psychotherapy in ... now seeing people of all ages as progression ... “Including children of all ages into parenting therapy ... Patricia O’Laughlin emphasizes. Patricia O’Laughlin Psychotherapy now specializes ...
(Date:5/22/2013)... IA (PRWEB) May 22, 2013 Diversity ... piece Handicap This! The performance promotes awareness that ... dreams. The Handicap This! performance will be held Friday, ... High School auditorium. Tickets for Handicap This! can ... This! helps audiences measure the level to which their ...
(Date:5/22/2013)... May 22, 2013 Today, Zane Benefits, ... Health Insurance Exchange . Zane Benefits, which provides comprehensive ... is the leader in defined contribution plans ... Zane Benefits’ website, beginning in 2014 as part of ... individuals and small businesses will become available through new ...
(Date:5/22/2013)... Over the next two decades, the cost of treating ... than double, topping more than $180 billion a year, ... the increase: an aging population. The report, from the ... was published May 22 in the journal Stroke ... system," Dr. Bruce Ovbiagele, chairman of the department of ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Award Presented ... Read the press release here: http://bit.ly/13DkFfk , ... was named “Information Management Product/Service of the Year” at ... March at The Colony Hotel in Palm Beach, Florida. ... virtual data room (VDR) solution that optimizes the ...
Breaking Medicine News(10 mins):Health News:Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children 2Health News:Handicap This! Comes to Marion, Iowa 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 3Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3
... change that has come to Washington is now needed ... leader in prevention.(Logo: http://www.newscom.com/cgi-bin/prnh/20080506/NETU129LOGO )"As the ... capital, the time is ripe to bring a fresh ... Christopher Fey, Chairman and CEO of U.S. Preventive Medicine. ...
... Inc.,(NYSE: HSP ), a leading global specialty pharmaceutical ... conference call to discuss its,fourth-quarter and full-year 2008 results and ... Central time. , The company will ... the U.S. stock market open and the conference,call. , ...
... As unemployment continues to,rise in the United States, Americans are ... what would happen if they were struck with a,serious medical ... pay for,the care? But the widely known benefit of hospice ... available to all eligible,Americans - whether they are employed or ...
... Americans who use illegal diet pills from South America ... both their health and their jobs. Physicians need to ... effects of these drugs to allow them to identify ... findings1, by Dr Pieter Cohen from the Department of ...
... 26, 2009) There is hope that the drug rasagiline ... does -- slow the progression of a devastating degenerative brain ... and function. , Now a new study looking at ... indicates that people who began the drug earlier continued to ...
... offers retailing veterans a 25% discount on the initial ... strongest and best franchise organizationPITTSBURGH, Jan. 26 Despite ... which has cost thousands of experienced retail employees their ... $21 billion industry and continues to grow at a ...
Cached Medicine News:Health News:U.S. Preventive Medicine Recommends Changing CDC Name to Centers for Disease Prevention and Control 2Health News:Hospice Care Remains a Misunderstood and Underutilized Benefit, According to In-House Hospice 2Health News:Hospice Care Remains a Misunderstood and Underutilized Benefit, According to In-House Hospice 3Health News:Caution: Lose more than weight with imported diet pills 2Health News:Patients starting Parkinson's drug rasagiline earlier do better 2Health News:Lost Your Job in Retail? Why Not Operate Your Own Business in 2009! Invest in You. Become an Entrepreneur! 2Health News:Lost Your Job in Retail? Why Not Operate Your Own Business in 2009! Invest in You. Become an Entrepreneur! 3
ELVeS is a new minimally-invasive laser treatment for patients with superficial vein reflux of the greater saphenous vein. The ELVeS laser treatment offers your patients an effective out-patient alt...
... EVLT, the #1 physician choice in laser ... to remedying superficial vein reflux. EVLT is ... surgical vein stripping that effectively and safely ... fiber to occlude the vein. The procedure ...
...
Inquire...
Medicine Products: